Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin and Erlotinib in Advanced NSCLC
NCT01104155Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2010
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of eribulin in non-small cell lung cancer (NSCLC), sponsored by Eisai Co., Ltd.. Started Feb 2010; status: completed.
02
Drugs
eribulin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01104155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01104155.